Anti-IgA
Test Code: 2107

Clinical and Procedure

Clinical Utility
For the evaluation of patients with recurrent infection for the possibility of IgA deficiency (IgAD). Patients with IgA deficiency may develop antibodies against IgA that make them susceptible to adverse reactions to blood products including intravenous immunoglobulin.

Procedure
ELISA using human polyclonal IgA coupled to the solid phase. This test has not been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.

Turnaround Time
5-8 business days from receipt of specimen

Specimen Information

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Order Code</th>
<th>CPT Code</th>
<th>NY Approved</th>
<th>Volume</th>
<th>Assay Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>serum</td>
<td>2107</td>
<td>83520</td>
<td>Yes</td>
<td>1 mL (min. 100 uL)</td>
<td>Reported in U/mL. Normal, healthy individuals who do not have anti-IgA antibodies contain &lt;99 U/mL. The reportable range is 16-1000 U/mL.</td>
</tr>
</tbody>
</table>

Special Instructions
- Collect 1 mL of serum.
- Blood should be collected and allowed to clot prior to centrifugation.
- Ship at ambient temperature Monday through Friday.
- Specimens are stable for 1 week ambient, 1 week refrigerated; > 2 weeks frozen.

Disclaimer
Specimens are approved for testing in New York only when indicated in the Specimen Information field above.

The CPT codes provided are based on Viracor Eurofins' interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for general informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor Eurofins assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.

References